Trophogen
 |
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
 |
|
| Type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Headquarters | Rockville, Maryland, 39 05' 48 N and 77 07'47 W |
| Key people | Bruce Weintraub, COO & CSO Mariusz Szkudlinski, VP Research and Development |
| Employees | 7 (2006) |
| Website | http://www.trophogen.com/ |
Trophogen, Inc. is a biotechnology company based in Rockville, Maryland.
Trophogen was formed by two molecular endocrinologists who spent numerous years as academians at NIH and the University of Maryland, Baltimore before striking out on their own to launch their first entrepreneurial endeavor.[1][2] Operating with staff of five scientists, their research is focused on the development of high affinity glycoprotein hormone and related growth factor analogs (FSH, LH and TSH) for targeted therapy and imaging of ovarian, breast, prostate, testicular and thyroid cancers as well as for human and animal infertility.[3]
Contents |
[edit] Research
Trophogen is dedicated to developing superactive hormones and growth factors for a wide array of therapeutic applications. Design of recombinant proteins with desired properties initially became possible in 1982 with the publishing of the first mutagenesis studies. In the past twenty years, however, successful examples of protein engineering have been rare. Trophogen's technology represents the first successful design of super active analogs of glycoprotein hormones that shows major increases in bioactivity and far exceeds results shown for other protein ligands.
[edit] Lead product candidates
- LH- and FSH superagonist- radionuclide or –toxin for the targeted therapy of ovarian cancer
- LH superagonist- radionuclide or –toxin for the targeted therapy of breast and prostate cancer
- TSH superagonist- radionuclide or –toxin for the targeted therapy of thyroid cancer
- TSH superagonist for enhancing 131I diagnostic scanning and treatment of thyroid cancer
- Labeled TSH superagonist imaging agent for thyroid cancer
- FSH and LH superagonist for the treatment of human and animal infertility
- VEGF superagonist for therapeutic targeting of tumor vasculature, vascular imaging and as a media supplement for endothelial and stem cell proliferation/differentiation
